Table 2 IC50 values for responses normalized to the control (DMSO), calculated by fitting a dose–response curve model in Graph Pad Prism and tabulated as concentration of drugs in µM. In cases where responses were above the highest drug concentration used in the experiment, IC50 estimates are marked as > 50 µM. Values in bold depict sensitive primary cells and cell lines, where IC50 to compounds < 10 µM and R2 (goodness of fit of curve) > 0.7).
From: Integrated genomics point to immune vulnerabilities in pleural mesothelioma
DNA repair | Hedgehog | Hippo | Cell cycle RB1 | |||||
|---|---|---|---|---|---|---|---|---|
Niraparib | Olaparib | Vismodegib | Verteporfin | Palbociclib | Alisertib | Volasertib | AZD7762 | |
Cell line | PARP inhibitors | SMO inhibitor | YAP inhibitor | CDK4/6 inhibitor | Aurora kinase inhibitor | PLK1 inhibitor | CHEK1 inhibitor | |
Meso-27T | 7.96 | 10.52 | 31.53 | 1.08 | > 50 | 3.20 | 6.57 | 0.45 |
Meso-33T | 47.02 | > 50 | 6.03 | 0.87 | 20.29 | 3.84 | 0.10 | 0.45 |
Meso-70T | > 50 | 2.88 | > 50 | 1.2 | > 50 | 0.15 | 0.04 | 2.02 |
NCI-H2052 | 29 | 27.3 | 13.7 | 10.9 | > 50 | 0.81 | 0.64 | 2.42 |
A549 | > 50 | 13.47 | 20.72 | 16.5 | 12.33 | 11.7 | 0.71 | 1.84 |
Met-5A | > 50 | 11.13 | 8.53 | 3.36 | 29.2 | > 50 | 0.44 | 0.11 |
